Edaravone, a treatment which is currently used overseas for people who have had a stroke, has been shown to be effective in reducing key Alzheimer’s disease toxic markers and improving cognition in mice, according to results recently published in the Journal PNAS.
The researchers from the University of South Australia and the Third Military Medical University in Chongqing, China injected Edaravone into mice with Alzheimer’s disease and found it reduced the build-up and formation of two key Alzheimer’s disease toxic proteins (amyloid beta and Tau) by up to 50%. It was also shown to suppress brain inflammation and preserve neuronal (brain cell) structures.
When these same mice underwent a variety of memory tests, they also showed improvements in memory and learning capabilities.
Find out more about this study at Dementia News.